Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Céline Mascaux

Citation

Annals of Oncology (2019) 30 (suppl_5): v671-v682. 10.1093/annonc/mdz263

Authors

C. Mascaux1, S. Sauvajeon2, J. Cadranel3, C. Chouaid4, J.B. Stern5, A. Vergnenegre6, C. Cortot7, L. Guery8, K. Belkhiria9, I. De la Porte10, M. Urbieta10, M. Perol11

Author affiliations

  • 1 Oncologie, Hôpitaux Universitaires de Strasbourg, 67000 - Strasbourg/FR
  • 2 Na, De l'Air, 69600 - Oullins/FR
  • 3 Pneumologie, Hôpital Tenon, 75020 - Paris/FR
  • 4 Pneumologie, CH Intercommunal de Créteil, 94010 - Créteil/FR
  • 5 Institut Du Thorax Curie Montsouris, Institut Mutualiste Montsouris, 75014 - Paris/FR
  • 6 Uotc Department- Unité Oncologie Thoracique Et Cutanée, CHU Limoges - Hopital Dupuytren, 87042 - Limoges/FR
  • 7 Oncologie, Astrazeneca France, 92400 - Courbevoie/FR
  • 8 Medical Department, Astrazeneca France, 92400 - Courbevoie/FR
  • 9 Medical Affairs, Astrazeneca, 92400 - Paris/FR
  • 10 Medical Affairs, Astrazeneca France, 92400 - Courbevoie/FR
  • 11 Pneumologie, Centre Léon Bérard, 69008 - Lyon/FR
More

Resources

Abstract 5101

Background

Recent reports suggested gaps in knowledge and misperceptions regarding lung cancer (LC) in the general public and physicians respectively. We aimed to further investigate the topic.

Methods

From February 21st to March 22nd, 2019, two online surveys were led in parallel among French people (n = 6001) and physicians (GP, n = 273; pulmonologists, n = 97; oncologists, n = 67). Questions aimed to assess people’s knowledge about LC prevalence, severity, diagnosis, management and treatments, early screening, as well of social stigma, and also understandings from physicians about public perception.

Results

LC was ranked as the 2nd most feared cancer (n = 1980; 33%) and perceived as very or extremely serious by 96% of people (n = 5760). Half of French people (n = 3360) declared knowing at least one other risk factor than tobacco, and except for asbestos (n = 5220; 87%), other potential risk factors were subjects to low to moderate levels of belief. The general population ranked LC as the 3rd easiest cancer to diagnose among French people (n = 2220; 37%) and 57% (n = 3420) believed that diagnosis was made early after symptoms onset. The general population was not aware of the majority of the symptoms beside blood in the sputum and respiratory symptoms. LC was ranked only the 5th cancer (n = 1260; 21%) among those for which medical progress had been the most substantial, whereas physicians ranked it second (n = 201; 46%). Also the public was not aware of therapeutic progress as immunotherapy. Physicians tended to be more optimistic about actual treatment improvement than the public and for 90% of them (n = 393), systematic screening of at-risk population would have a significant impact on mortality data by LC.

Conclusions

Our study confirms the substantial gaps in LC knowledge from the general public and highlights several venues for improvement of communication and public awareness on LC in France.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

J. Cadranel: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Boerhinger Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: BMS; Advisory / Consultancy: Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda. C. Chouaid: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: GSK; Advisory / Consultancy: Roche; Advisory / Consultancy: Sanofi Aventis; Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: Lilly; Advisory / Consultancy: Novartis; Advisory / Consultancy: Amgen. J.B. Stern: Speaker Bureau / Expert testimony, Fees for presentation in a Medtronic symposium which were donated to our association.: Medtronic. A. Vergnenegre: Advisory / Consultancy, Research grant / Funding (institution): Roche; Research grant / Funding (institution): Chugai; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Teva; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Clovis Oncology. C. Cortot: Full / Part-time employment: AstraZeneca. L. Guery: Full / Part-time employment: AstraZeneca. K. Belkhiria: Full / Part-time employment: AstraZeneca. I. De la Porte: Full / Part-time employment: AstraZeneca. M. Urbieta: Full / Part-time employment: AstraZeneca. M. Perol: Advisory / Consultancy: Novartis; Advisory / Consultancy: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings